Bioventus (BVS) Cash from Financing Activities (2020 - 2026)
Bioventus (BVS) posted Cash from Financing Activities of -$23.1 million for Q1 2026, up 18.64% on a QoQ basis from -$28.4 million in Q4 2025, and down 2543.93% year-over-year from $947000.0 in Q1 2025.
Bioventus (BVS) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Bioventus' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$23.1 million for Q1 2026.
- Quarterly Cash from Financing Activities fell 2543.93% year-over-year to -$23.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$86.2 million (down 74.59% YoY) and the FY2025 annual result came in at -$62.1 million, down 13.85% from the prior year.
- Cash from Financing Activities was -$23.1 million for Q1 2026 at Bioventus, up from -$28.4 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $50.7 million in Q4 2022 and bottomed at -$62.2 million in Q3 2023.
- A 5-year average of -$6.1 million and a median of -$4.2 million in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 1265.53% — and 2024, when it slumped 306007.14%.
- Bioventus' Cash from Financing Activities stood at -$5.4 million in 2022, then jumped by 99.74% to -$14000.0 in 2023, then slumped by 306007.14% to -$42.9 million in 2024, then jumped by 33.62% to -$28.4 million in 2025, then gained by 18.64% to -$23.1 million in 2026.
- Business Quant data shows BVS's Cash from Financing Activities at -$23.1 million in Q1 2026, -$28.4 million in Q4 2025, and -$20.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.54 Bn | 176.24 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 129.03 Bn | 126.15 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 108.43 Bn | 99.21 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 68.74 Bn | 67.28 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 48.34 Bn | 44.67 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 28.35 Bn | 27.24 Bn | 750.30 Mn | -25.00 Mn |
| 7 | GE HealthCare Technologies | 28.07 Bn | 25.78 Bn | 1.98 Bn | 21.00 Mn |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - | - |
| 9 | Koninklijke Philips | 24.06 Bn | 20.93 Bn | 2.07 Bn | -26.93 Mn |
| 10 | Bioventus | 824.72 Mn | 788.87 Mn | 90.77 Mn | -23.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | -23.14 Mn |
| Mar 28, 2026 | -23.14 Mn |
| Dec 31, 2025 | -28.45 Mn |
| Dec 31, 2025 | -28.45 Mn |
| Sep 27, 2025 | -19.98 Mn |
| Sep 27, 2025 | -19.98 Mn |
| Jun 28, 2025 | -14.66 Mn |
| Jun 28, 2025 | -14.66 Mn |
| Mar 29, 2025 | 947,000.00 |
| Mar 29, 2025 | 947,000.00 |
| Dec 31, 2024 | -42.86 Mn |
| Dec 31, 2024 | -42.86 Mn |
| Sep 28, 2024 | 362,000.00 |
| Sep 28, 2024 | 362,000.00 |
| Jun 29, 2024 | -7.85 Mn |
| Jun 29, 2024 | -7.85 Mn |
| Mar 30, 2024 | -4.24 Mn |
| Mar 30, 2024 | -4.24 Mn |
| Dec 31, 2023 | -14,000.00 |
| Dec 31, 2023 | -14,000.00 |